Literature DB >> 12885439

Adenosine triphosphate inhibits cytokine release from lipopolysaccharide-activated microglia via P2y receptors.

Tadanori Ogata1, Miao Chuai, Tadao Morino, Haruyasu Yamamoto, Yoichi Nakamura, Peter Schubert.   

Abstract

Microglial proliferation and activation have been reported to occur after several central nervous system injuries. In this study, we tested the effects of adenosine triphosphate (ATP) on cultured microglia obtained from the spinal cord of rat embryos. The amounts of tumor necrosis factor alpha (TNF-alpha), interleukin 1beta and interleukin 6 released from the microglia, which were stimulated by lipopolysaccharide (LPS; 100 ng/ml), were inhibited by the simultaneous addition of ATP in a dose dependent manner (10-300 microM). We examined the effect of several endogenous purines (ATP, ADP, CTP, UDP, UTP) and P(2)y receptor agonists (ADPbetaS and 2-methylthio-ATP) on LPS-induced TNF-alpha release. The rank order of inhibitory potency of endogenous purines on TNF-alpha release was: ATP>ADP>>UTP>UDP>CTP. The latter three were much less potent than the former two. The addition of 10 microM 2-methylthio-ATP showed a potency similar to 100 microM ATP. The addition of ADPbetaS, however, showed less effect. These endogenous purines and selective ATP receptor agonists showed a similar inhibitory effect in their rank order on LPS-induced interleukin 6 release. We demonstrate that ATP inhibits cytokine release from LPS-activated microglia via metabotropic receptors. The application of P(2)y receptor agonists might be considered as a pharmacological treatment of several pathological conditions of the spinal cord, including toxic immunoreactions.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12885439     DOI: 10.1016/s0006-8993(03)03028-2

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  16 in total

1.  Estrogen and P2 Purinergic Receptor Systems in Microglia: Therapeutic Targets for Neuroprotection.

Authors:  Jessica M Crain; Jyoti J Watters
Journal:  Open Drug Discov J       Date:  2010-01-01

Review 2.  Role of microglia in central nervous system infections.

Authors:  R Bryan Rock; Genya Gekker; Shuxian Hu; Wen S Sheng; Maxim Cheeran; James R Lokensgard; Phillip K Peterson
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

Review 3.  Purinergic signaling and microglia.

Authors:  Katrin Färber; Helmut Kettenmann
Journal:  Pflugers Arch       Date:  2006-06-21       Impact factor: 3.657

4.  The P2X7-Egr pathway regulates nucleotide-dependent inflammatory gene expression in microglia.

Authors:  S A Friedle; V M Brautigam; M Nikodemova; M L Wright; J J Watters
Journal:  Glia       Date:  2010-09-27       Impact factor: 7.452

Review 5.  Microglial phenotype and adaptation.

Authors:  B J L Eggen; D Raj; U-K Hanisch; H W G M Boddeke
Journal:  J Neuroimmune Pharmacol       Date:  2013-07-25       Impact factor: 4.147

Review 6.  Integrating neuroimmune systems in the neurobiology of depression.

Authors:  Eric S Wohleb; Tina Franklin; Masaaki Iwata; Ronald S Duman
Journal:  Nat Rev Neurosci       Date:  2016-06-09       Impact factor: 34.870

7.  P2Y14 receptor activation decreases interleukin-6 production and glioma GL261 cell proliferation in microglial transwell cultures.

Authors:  Marjorie A Curet; Jyoti J Watters
Journal:  J Neurooncol       Date:  2017-11-30       Impact factor: 4.130

Review 8.  Microglia during development and aging.

Authors:  G Jean Harry
Journal:  Pharmacol Ther       Date:  2013-04-30       Impact factor: 12.310

9.  ATP stimulates chemokine production via a store-operated calcium entry pathway in C6 glioma cells.

Authors:  Nattinee Jantaratnotai; Hyun B Choi; James G McLarnon
Journal:  BMC Cancer       Date:  2009-12-15       Impact factor: 4.430

10.  Expression of P2 nucleotide receptors varies with age and sex in murine brain microglia.

Authors:  Jessica M Crain; Maria Nikodemova; Jyoti J Watters
Journal:  J Neuroinflammation       Date:  2009-08-25       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.